CIK 0001737953
- Non-accelerated filer
- Smaller reporting company
Replimune Group, Inc.
Sign in to watch- Ticker
- REPL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 822082553
- Phone
- +1 781-222-9600
- Business address
- 500 UNICORN PARK, WOBURN, MA, 01801
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $521,860
- in 2 filings
Net −$521,860. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 83 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-08-04 | Esposito Pamela Chief Business Officer | Sale | −4,200 | $35.00 | $147K | 210,159 |
| 2021-08-04 | Esposito Pamela Chief Business Officer | Option exercise · Employee Stock Option (right to buy) | −4,200 | 71,550 | ||
| 2021-07-21 | Esposito Pamela Chief Business Officer | Option exercise | +12,538 | $1.01 | $13K | 222,697 |
| 2021-07-21 | Esposito Pamela Chief Business Officer | Sale | −12,538 | $33.17 | $416K | 210,159 |
| 2021-07-21 | Esposito Pamela Chief Business Officer | Option exercise · Employee Stock Option (right to buy) | −12,538 | 51,203 | ||
| 2021-07-20 | Esposito Pamela Chief Business Officer | Option exercise | +4,862 | $1.01 | $5K | 215,021 |
| 2021-07-20 | Esposito Pamela Chief Business Officer | Sale | −4,862 | $33.05 | $161K | 210,159 |
| 2021-07-20 | Esposito Pamela Chief Business Officer | Option exercise · Employee Stock Option (right to buy) | −4,862 | 63,741 | ||
| 2021-07-15 | Esposito Pamela Chief Business Officer | Option exercise | +4,600 | $1.01 | $5K | 214,759 |
| 2021-07-15 | Esposito Pamela Chief Business Officer | Sale | −4,600 | $33.37 | $154K | 210,159 |
| 2021-07-15 | Esposito Pamela Chief Business Officer | Option exercise · Employee Stock Option (right to buy) | −4,600 | 68,603 | ||
| 2021-07-15 | Love Colin Chief Operating Officer | Sale | −30,000 | $32.02 | $961K | 835,809 |
| 2021-07-02 | Coffin Robert President & Chief R&D Officer | Sale | −7,810 | $40.04 | $313K | 1,775,684 |
| 2021-06-29 | Coffin Robert President & Chief R&D Officer | Sale | −22,826 | $40.05 | $914K | 1,783,494 |
| 2021-06-28 | Coffin Robert President & Chief R&D Officer | Sale | −14,663 | $40.04 | $587K | 1,806,320 |
| 2021-06-15 | Love Colin Chief Operating Officer | Sale | −17,800 | $33.80 | $602K | 878,009 |
| 2021-06-15 | Love Colin Chief Operating Officer | Sale | −12,200 | $34.53 | $421K | 865,809 |
| 2021-05-10 | Lewis Tanya Chief Dev. Oper. Off. | Grant or award | +73,333 | 73,333 | ||
| 2021-05-10 | Lewis Tanya Chief Dev. Oper. Off. | Grant or award · Employee Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2021-05-03 | Patel Sushil Chief Commercial Officer | Grant or award | +88,333 | 88,333 |
Page 13 of 19 · 365 trades